Scoop: J&J confirms that the FDA put AML drug on complete hold
J&J tells Endpoints News that a bispecific antibody it is partnered on with Genmab for acute myeloid leukemia has been put on clinical hold after patients in the trial suffered serious adverse events.
The drug, JNJ-63709178, targets both CD3 and CD123 and was in an early stage study when the hold was instituted, forcing investigators to suspend patient recruitment, according to the clinicaltrials.gov web site. The complete hold, which should stop dosing, followed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
